Zacks Research Brokers Lower Earnings Estimates for TSE:BHC

Key Points

• Zacks Research lowered its FY2025 earnings per share estimate for Bausch Health Companies Inc. to $5.23, down from the previous estimate of $5.27.
• The company's stock opened at C$10.43, with a market capitalization of C$2.71 billion and a price-to-earnings ratio of -15.26.
• Insiders, including Director John Paulson, purchased over 3.5 million shares of the company's stock recently, indicating confidence in the firm's future.

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities research analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a report released on Wednesday, August 20th. Zacks Research analyst Team now expects that the company will post earnings of $5.23 per share for the year, down from their previous forecast of $5.27. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.66 EPS, Q3 2026 earnings at $1.61 EPS, FY2026 earnings at $5.64 EPS, Q1 2027 earnings at $1.43 EPS, Q2 2027 earnings at $1.43 EPS and FY2027 earnings at $6.39 EPS.

Bausch Health Companies Price Performance

Shares of TSE:BHC opened at C$10.43 on Friday. The company has a debt-to-equity ratio of -1,831.94, a current ratio of 1.19 and a quick ratio of 0.58. Bausch Health Companies has a 12 month low of C$5.91 and a 12 month high of C$13.74. The firm has a market capitalization of C$2.71 billion, a price-to-earnings ratio of -15.26, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The business's 50 day simple moving average is C$9.01 and its 200-day simple moving average is C$8.43.

Insider Activity

In related news, Director John Paulson acquired 1,782,030 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of C$8.14 per share, for a total transaction of C$14,501,803.73. In the last three months, insiders purchased 3,553,401 shares of company stock worth $27,087,675. Insiders own 11.28% of the company's stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.